Literature DB >> 35541032

Immunocytochemistry of effusion fluids: Introduction to SCIP approach.

Vinod B Shidham1, Lester J Layfield2.   

Abstract

Due to the remarkably wide morphologic spectrum of reactive mesothelial cells, some of the effusion fluids may be difficult to interpret with objective certainty by cytomorphology alone. Cytomorphology of well to moderately differentiated adenocarcinomas (responsible for the bulk of malignant effusions) may overlap with floridly reactive mesothelial cells. Even mesotheliomas including diffuse malignant epithelioid mesothelioma, are usually cytomorphologically bland without unequivocal features of malignancy. The intensity of challenge depends on the interpreter's training or experience level, institutional demographics of patients (such as type of prevalent diseases, predominant sex and age group), technical support, and quality of cytopreparatory processing. In general immunocytochemistry is valuable adjunct to facilitate objective interpretation with or without other ancillary techniques as indicated. An increasing number of immunomarkers is further refining the contribution of immunohistochemistry to this field. However, application of immunohistochemistry to effusion fluids is relatively challenging because of many variables. Multiple factors such as delay after specimen collection, specimen processing related factors including fixation and storage; ambient conditions under which paraffin blocks are archived (for retrospective testing); antigen retrieval method; duration of antigen retrieval step; antibody clone and dilution; and antibody application time are identical to application of immunohistochemistry in other areas. The significant challenge related to the potential compromization of the immunoreactivity pattern due to exposure to non-formalin fixatives / reagents is also applicable to effusion fluid specimens. The immunoreactivity results would be compared and corelated with cumulative metadata based on the reported studies performed and validated on formalin-fixed paraffin-embedded tissue sections. Deviating from such protocols may lead to suboptimal results, which is not uncommon in clinical practice with potential compromization of patient care and related liability. Because of this, it is critical to perform immunocytochemistry on formalin-fixed cell-block sections only. In addition, unless the interpretation criteria for immunohistochemical evaluation of effusion fluids are not modified specifically, it may not be productive in resolving some challenging cases. However, this aspect is not well elaborated in the literature. A basic and critical challenge is finding and locating the cells of interest in cell-block sections of effusion fluids. A unique approach is to choose a fundamental immunopanel which highlight the mesothelial and inflammatory cells in reactive effusion fluids to create the basic map. This allows detection of a 'second-foreign' population which can be immunocharacterized further with the help of subtractive coordinate immunoreactivity pattern (SCIP) approach elaborated here.
© 2022 Cytopathology Foundation Inc, Published by Scientific Scholar.

Entities:  

Keywords:  Immunocytochemistry; Immunohistochemistry; SCIP; cell-block; cytology; effusions; formalin fixation

Year:  2022        PMID: 35541032      PMCID: PMC9079320          DOI: 10.25259/CMAS_02_05_2021

Source DB:  PubMed          Journal:  Cytojournal        ISSN: 1742-6413            Impact factor:   2.345


  78 in total

1.  N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: a ThinPrep immunocytochemical study.

Authors:  A C Han; M R Filstein; J V Hunt; A P Soler; K A Knudsen; H Salazar
Journal:  Cancer       Date:  1999-04-25       Impact factor: 6.860

2.  Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.

Authors:  P A Fetsch; A Abati; Y M Hijazi
Journal:  Cancer       Date:  1998-04-25       Impact factor: 6.860

Review 3.  The immunohistochemistry of malignant mesothelioma.

Authors:  A S Leong; E Vernon-Roberts
Journal:  Pathol Annu       Date:  1994

4.  E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless.

Authors:  A Simsir; P Fetsch; D Mehta; M Zakowski; A Abati
Journal:  Diagn Cytopathol       Date:  1999-03       Impact factor: 1.582

Review 5.  The immunohistochemical diagnosis of epithelial mesothelioma.

Authors:  N G Ordóñez
Journal:  Hum Pathol       Date:  1999-03       Impact factor: 3.466

6.  Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.

Authors:  Kyra B Berg; Sanja Dacic; Caitlyn Miller; Simon Cheung; Andrew Churg
Journal:  Arch Pathol Lab Med       Date:  2018-07-30       Impact factor: 5.534

7.  D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.

Authors:  Nelson G Ordóñez
Journal:  Hum Pathol       Date:  2005-04       Impact factor: 3.466

8.  An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.

Authors:  U Brockstedt; M Gulyas; K Dobra; A Dejmek; A Hjerpe
Journal:  Am J Clin Pathol       Date:  2000-08       Impact factor: 2.493

9.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.

Authors:  R L Attanoos; A Griffin; A R Gibbs
Journal:  Histopathology       Date:  2003-09       Impact factor: 5.087

10.  Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis.

Authors:  Chao He; Bo Wang; Chun Wan; Ting Yang; Yongchun Shen
Journal:  Oncotarget       Date:  2017-07-06
View more
  3 in total

Review 1.  Mesothelioma.

Authors:  Nagarjun Rao; Shuanzeng Wei
Journal:  Cytojournal       Date:  2022-02-28       Impact factor: 2.345

Review 2.  Serous fluid: Reactive conditions.

Authors:  Nirag Jhala; Darshana Jhala; Vinod B Shidham
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

Review 3.  Serous cavity metastasis: Evaluation of unknown primary.

Authors:  Nirag Jhala; Aileen Arriola; Liron Pantanowitz
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.